Skip to Content

What type of cancer is Tecentriq used to treat?

Medically reviewed by Judith Stewart, BPharm. Last updated on Feb 16, 2021.

Official Answer

by Drugs.com

Tecentriq (atezolizumab) is used to treat:

Tecentriq was the first programmed death-ligand 1 (PD-L1) blocking antibody approved by the FDA.

Tecentriq belongs to a class of immunotherapy drugs called immune checkpoint inhibitors and works by boosting the body’s immune system to help it attack cancer cells. Immune checkpoint inhibitors may also allow the immune system to attack normal organs in the body which may lead to serious side effects, but overall these drugs are better tolerated than many of the older standard cancer treatments.

Common side effects with Tecentriq may include fatigue, loss of appetite, and nausea. Other more serious side effects may include hepatitis, inflammation in the lungs, intestines, or other organs.

Tecentriq Indications

Urothelial Carcinoma

  • Tecentriq is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who:
    • are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), as determined by an FDA-approved test, or
    • are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status, or
    • have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Non-Small Cell Lung Cancer (NSCLC)

  • Tecentriq is indicated for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA approved test, with no EGFR or ALK genomic tumor aberrations.
  • Tecentriq is indicated in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
  • Tecentriq is indicated in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
  • Tecentriq is indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
    Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving Tecentriq.

Triple-Negative Breast Cancer (TNBC)

  • Tecentriq is indicated in combination with paclitaxel protein-bound for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA approved test. This indication is approved under accelerated approval based on progression free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Small Cell Lung Cancer (SCLC)

  • Tecentriq is indicated in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).

Heptatocellular Carcinoma (HCC)

  • Tecentriq is indicated in combination with bevacizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy.

Melanoma

  • Tecentriq is indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
References
  • Food and Drug Administration. TECENTRIQ Product Label. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761034s031s032lbl.pdf [Accessed February 16, 2021]

Related Medical Questions

Drug Information

Related Support Groups